David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary
January 25 2022 - 4:01PM
Delcath Systems, Inc. (NASDAQ:
DCTH), an
interventional oncology company focused on the treatment of primary
and metastatic cancers of the liver, today announced
that David Hoffman has been appointed as General Counsel and
Corporate Secretary. Mr. Hoffman will also serve as Delcath’s Chief
Compliance Officer.
Mr. Hoffman brings over 20 years of experience advising
biotechnology companies with a focus on the commercialization of
therapies. Most recently, he served as Associate General Counsel
and Chief Compliance Officer at Vericel Corporation, where he
was responsible for legal and compliance matters and supported the
launch and growth of products in the advanced cell therapy and
biologics space. Mr. Hoffman has considerable expertise in
healthcare and pharmaceutical law and regulation, business
development, commercial business transactions, mergers and
acquisitions, intellectual property, compliance, and securities
law.
“The addition of David to our team brings important perspective
and experience to the Company at this critical juncture,”
said Gerard Michel, Chief Executive Officer of Delcath.
“His background and counsel will be a crucial asset as we continue
to progress on our mission to commercialize new therapies to treat
cancers of the liver.”
Prior to his role at Vericel, Mr. Hoffman held senior legal
positions at Sunovion Pharmaceuticals, where he oversaw the legal
teams responsible for commercial, medical, and research activities.
Mr. Hoffman began his legal career at Arnall Golden Gregory
LLP in Atlanta and Mr. Hoffman holds a B.S. in Civil Engineering
and M.S. in Environmental Engineering both from Clemson
University and a J.D. from Georgia State University
School of Law.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company’s proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being
developed under the tradename HEPZATO KIT (melphalan hydrochloride
for injection/hepatic delivery system), or HEPZATO, and is
considered a combination drug and device product regulated by
the United States Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb
medical device and is approved for sale under the trade name
CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where
it has been used at major medical centers to treat a wide range of
cancers of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024